{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T18:26:13Z","timestamp":1648751173027},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s00120-012-2808-7","type":"journal-article","created":{"date-parts":[[2012,4,3]],"date-time":"2012-04-03T16:44:03Z","timestamp":1333471443000},"page":"557-566","source":"Crossref","is-referenced-by-count":2,"title":["Antiandrogene Therapie des Prostatakarzinoms"],"prefix":"10.1007","volume":"51","author":[{"given":"J.","family":"Rohayem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kliesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,5]]},"reference":[{"key":"2808_CR1","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0022-5347(02)80307-X","volume":"167","author":"Huggins","year":"2002","unstructured":"Huggins C, Hodges CV (2002) Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 167:948\u2013951","journal-title":"J Urol"},{"key":"2808_CR2","first-page":"675","volume":"Urol","author":"Schulman","year":"2010","unstructured":"Schulman CC, Irani J, Morote J et al (2010) Androgen-deprivation therapy in prostate cancer: a European expert panel review. Eur Urol (Suppl 9):675\u2013691","journal-title":"Eur"},{"key":"2808_CR3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","volume":"59","author":"Mottet","year":"2011","unstructured":"Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59:572\u2013583","journal-title":"Eur Urol"},{"key":"2808_CR4","unstructured":"Leitlinienprogramm Onkologie der AWMW, Deutschen Krebsgesellschaft e.\u00a0V., Deutschen Krebshilfe e.\u00a0V. (2011) Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S 3 zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Version 2.0\u20131. Aktualisierung 2011"},{"key":"2808_CR5","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","volume":"68","author":"Locke","year":"2008","unstructured":"Locke JA, Guns ES, Lubik AA et al (2008) Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407\u20136415","journal-title":"Cancer Res"},{"key":"2808_CR6","first-page":"1281","volume":"31","author":"Leuprolide","year":"1984","unstructured":"Leuprolide Study Group (1984) Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 31:1281\u20131286","journal-title":"N Engl J Med"},{"key":"2808_CR7","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/0022-4731(83)90046-8","volume":"19","author":"Labrie","year":"1983","unstructured":"Labrie F, Dupont A, Belanger A et al (1983) New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen. J Steroid Biochem 19:999\u20131007","journal-title":"J Steroid Biochem"},{"key":"2808_CR8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0022-4731(86)90043-9","volume":"24","author":"Moguilewsky","year":"1986","unstructured":"Moguilewsky M, Fiet J, Tournemine C, Raynaud JP (1986) Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer. J Steroid Biochem 24:139\u2013146","journal-title":"J Steroid Biochem"},{"key":"2808_CR9","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","volume":"355","author":"Prostate","year":"2000","unstructured":"Prostate Cancer Trialists\u2018 Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355:1491\u20131498","journal-title":"Lancet"},{"key":"2808_CR10","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","volume":"22","author":"Small","year":"2004","unstructured":"Small EJ, Halabi S, Dawson NA et al (2004) Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22:1025\u20131033","journal-title":"J Clin Oncol"},{"key":"2808_CR11","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"Bono","year":"2011","unstructured":"Bono JS de, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995\u20132005","journal-title":"N Engl J Med"},{"key":"2808_CR12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"Chen","year":"2004","unstructured":"Chen CD, Welsbie DS, Tran C et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33\u201339","journal-title":"Nat Med"},{"key":"2808_CR13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/1078-0432.CCR-1146-03","volume":"10","author":"Mohler","year":"2004","unstructured":"Mohler JL, Gregory CW, Ford OH 3rd et al (2004) The androgen axis in recurrent prostate cancer. Clin Cancer Res 10:440\u2013448","journal-title":"Clin Cancer Res"},{"key":"2808_CR14","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3109\/00365599.2011.585820","volume":"45","author":"Hedlund","year":"2011","unstructured":"Hedlund PO, Johansson R, Damber JE et al (2011) Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial. Scand J Urol Nephrol 45:346\u2013353","journal-title":"Scand J Urol Nephrol"},{"key":"2808_CR15","first-page":"117","volume":"5","author":"Paller","year":"2011","unstructured":"Paller CJ, Antonarakis ES (2011) Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther 5:117\u2013124","journal-title":"Drug Des Devel Ther"},{"key":"2808_CR16","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1055\/s-2008-1047713","volume":"122","author":"Kliesch","year":"1997","unstructured":"Kliesch S, Behre HM, Roth S (1997) Rationale Therapie der Hitzewallungen unter Hormonentzugsbehandlung bei Patienten mit fortgeschrittenem Prostatakarzinom. Dtsch Med Wochenschr 122:940\u2013945","journal-title":"Dtsch Med Wochenschr"},{"key":"2808_CR17","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","volume":"91","author":"Smith","year":"2006","unstructured":"Smith MR, Lee H, Nathan DM (2006) Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91:1305\u20131308","journal-title":"J Clin Endocrinol Metab"},{"key":"2808_CR18","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.juro.2009.01.047","volume":"181","author":"Saylor","year":"2009","unstructured":"Saylor PJ, Smith MR (2009) Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 181:1998\u20132006","journal-title":"J Urol"},{"key":"2808_CR19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","volume":"121","author":"Levine","year":"2010","unstructured":"Levine GN, D\u2019Amico AV, Berger P et al (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121:833\u2013840","journal-title":"Circulation"},{"key":"2808_CR20","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/jbmr.405","volume":"26","author":"Melton","year":"2011","unstructured":"Melton LJ 3rd, Lieber MM, Atkinson EJ et al (2011) Fracture risk in men with prostate cancer: a population-based study. J Bone Miner Res 26:1808\u20131815","journal-title":"J Bone Miner Res"},{"key":"2808_CR21","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1055\/s-0028-1105855","volume":"133","author":"Jacobeit","year":"2008","unstructured":"Jacobeit JW, Kliesch S (2008) Gyn\u00e4komastie: Diagnostik und Therapie. Dtsch Med Wochenschr 133:2567\u20132571","journal-title":"Dtsch Med Wochenschr"},{"key":"2808_CR22","doi-asserted-by":"crossref","unstructured":"Prommer E (2011) Methylphenidate: established and expanding roles in symptom management. Am J Hosp Palliat Care [Epub ahead of print]","DOI":"10.1177\/1049909111427029"},{"key":"2808_CR23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.maturitas.2009.10.017","volume":"65","author":"Frisk","year":"2010","unstructured":"Frisk J (2010) Managing hot flushes in men after prostate cancer \u2013 a systematic review. Maturitas 65:15\u201322","journal-title":"Maturitas"},{"key":"2808_CR24","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.apmr.2010.11.015","volume":"92","author":"Cicerone","year":"2011","unstructured":"Cicerone KD, Langenbahn DM, Braden C et al (2011) Evidence-based cognitive rehabilitation: updated review of the literature from 2003 through 2008. Arch Phys Med Rehabil 92:519\u2013530","journal-title":"Arch Phys Med Rehabil"},{"key":"2808_CR25","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.juro.2007.08.007","volume":"178","author":"Teloken","year":"2007","unstructured":"Teloken PE, Ohebshalom M, Mohideen N, Mulhall JP (2007) Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer. J Urol 178:2521\u20132525","journal-title":"J Urol"},{"key":"2808_CR26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/pcan.2011.4","volume":"15","author":"Serpa","year":"2011","unstructured":"Serpa Neto A, Tobias-Machado M, Esteves MA et al (2011) Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 15(1):36\u201344","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2808_CR27","unstructured":"Langenhuijsen JF, Badhauser D, Schaaf B et al (2011) Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol [Epub ahead of print]"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-012-2808-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-012-2808-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-012-2808-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T17:48:24Z","timestamp":1561571304000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-012-2808-7"}},"subtitle":["Indikation und systemische Folgen"],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["2808"],"URL":"https:\/\/doi.org\/10.1007\/s00120-012-2808-7","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}